Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Sales (2020 - 2025)

Apellis Pharmaceuticals has reported Return on Sales over the past 6 years, most recently at 1.02% for Q4 2025.

  • Quarterly results put Return on Sales at 1.02% for Q4 2025, down 95.0% from a year ago — trailing twelve months through Dec 2025 was 0.12% (up 10.0% YoY), and the annual figure for FY2025 was 0.12%, up 10.0%.
  • Return on Sales for Q4 2025 was 1.02% at Apellis Pharmaceuticals, down from 0.47% in the prior quarter.
  • Over the last five years, Return on Sales for APLS hit a ceiling of 17.77% in Q4 2022 and a floor of 351.83% in Q2 2021.
  • Median Return on Sales over the past 5 years was 0.81% (2023), compared with a mean of 20.13%.
  • Biggest five-year swings in Return on Sales: plummeted -2691bps in 2021 and later surged 34228bps in 2022.
  • Apellis Pharmaceuticals' Return on Sales stood at 4.7% in 2021, then soared by 278bps to 17.77% in 2022, then tumbled by -103bps to 0.61% in 2023, then surged by 89bps to 0.06% in 2024, then crashed by -1488bps to 1.02% in 2025.
  • The last three reported values for Return on Sales were 1.02% (Q4 2025), 0.47% (Q3 2025), and 0.24% (Q2 2025) per Business Quant data.